Shenzhen Salubris Pharmaceuticals Hits Day High with Strong 3.42% Surge

Shenzhen Salubris Pharmaceuticals Co., Ltd. has experienced a notable increase of 3.42% on September 25, 2025, reaching an intraday high of CNY 65.63. This performance stands in contrast to the China Shanghai Composite, which rose by only 0.83% on the same day. Over the past week, Shenzhen Salubris has shown a robust gain of 14.31%, significantly outperforming the broader market, which declined by 0.59%.
In terms of longer-term performance, Shenzhen Salubris has demonstrated impressive growth, with a 102.01% increase over the past year and a remarkable 173.25% rise over the last three years. The company's market capitalization is currently CNY 61,030 million, classifying it as a large-cap entity within the Pharmaceuticals & Biotechnology sector.

Despite a recent decline in profits of 3.2%, the stock has maintained a high dividend yield of 2.3% and a return on equity of 7.28%. The company's price-to-book ratio stands at 7.15, indicating a strong valuation relative to its assets. Overall, Shenzhen Salubris continues to show resilience and consistent returns in a competitive market landscape.